Profilo
William D.
Milligan is Senior Vice President of Corporate Development and Chief Business Officer of MIGENIX, Inc. which he joined in April 2002.
He has been a Director of ViRexx Medical Corp.
since September 14, 2008.
Prior to joining MIGENIX, he was President and Chief Executive Officer of Cytran, Inc. and Chief Executive Officer of Intellivax International, Inc. Prior to joining Intellivax, Mr. Milligan served 8 years with Hoffmann-La Roche Ltd., where he held various executive positions, including Vice President of Business Development and New Product Planning, Vice President of the Sales Division-Pharmaceuticals and Vice President of the Biomedical Division.
Prior to joining Hoffmann-LaRoche, he held various marketing and sales management positions for over 8 years with Eli Lilly Canada, Inc. Mr. Milligan received a BS in Biology from the University of Calgary.
Precedenti posizioni note di William D. Milligan
| Società | Posizione | Fine |
|---|---|---|
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 31/01/2009 |
ViRexx Medical Corp.
 ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Direttore/Membro del Consiglio | 23/12/2008 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Vendite & Marketing | - |
Intellivax International, Inc.
 Intellivax International, Inc. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Intellivax International, Inc. is a Canadian company that develops nasal spray vaccines. The company is based in Laval, Canada. The company was founded by George H. Lowell. Intellivax International was acquired by ID Biomedical Corp., part of GSK Plc from December 13, 2005 on May 16, 2001 for $15.44 million. | Presidente | - |
| Cytran, Inc. | Presidente | - |
Formazione di William D. Milligan
| University of Calgary | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |
ViRexx Medical Corp.
ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Health Technology |
| Cytran, Inc. | |
Intellivax International, Inc.
Intellivax International, Inc. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Intellivax International, Inc. is a Canadian company that develops nasal spray vaccines. The company is based in Laval, Canada. The company was founded by George H. Lowell. Intellivax International was acquired by ID Biomedical Corp., part of GSK Plc from December 13, 2005 on May 16, 2001 for $15.44 million. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
- Borsa valori
- Insiders
- William D. Milligan
